We investigated the hypothesis that reduced glutathione (GSH) is present in secretions of the female reproductive tract and that this extracellular GSH may protect preimplantation mouse embryos after intracellular GSH depletion. The cleavagestage mouse embryo cannot synthesize GSH de novo and is unable to recover from glutathione depletion in vitro. Analysis of GSH and total protein of oviduct flushings, quantified by HPLC and the Bradford method, respectively, revealed 51 nmol GSH per mg total protein. Embryos were treated with 60 M diethyl maleate (DEM) to deplete cellular GSH. When cultured with 1 mM GSH, these embryos exhibited improved development compared to those cultured in control medium (96% vs. 87% morula [p Ͻ 0.05], 78% vs. 75% blastocyst, 58% vs. 54% expanded blastocyst, 21% vs. 17% initiating hatching blastocyst). However, intracellular GSH content of embryos was not significantly increased by the culture of DEM-treated embryos in medium containing GSH for 16, 40, or 64 h of incubation, suggesting that the embryo is not capable of taking up intact GSH. Furthermore, addition of buthionine sulfoximine (which inhibits synthesis of GSH) or acivicin (which inhibits breakdown of GSH at the membrane) to culture medium blocked the improvement in development. These data suggest that GSH in reproductive tract fluid may help protect preimplantation embryos from the adverse effects of toxicant-induced and endogenous depletion of embryonic GSH.
INTRODUCTION
Reduced glutathione (GSH; ␥-glutamylcysteinylglycine) serves as a storage and transport form of cysteine, protects cells from toxicants, functions as a redox buffer, and protects cells from reactive oxygen species generated by normal oxidative metabolism [1] . GSH protects against reactive oxygen species directly and by serving as a substrate for GSH peroxidase, resulting in the oxidation of GSH. Glutathione reductase (EC 1.6.4.2) regenerates GSH from oxidized glutathione (GSSG) using NADPH. GSH is synthesized de novo in a two-step process. ␥-Glutamylcysteine synthetase (EC 6.3.2.2) is the rate-limiting enzyme and is inhibited by buthionine sulfoximine (BSO) [2] . The second reaction is catalyzed by glutathione synthetase (EC 6.3.2.3). ␥-Glutamyl transpeptidase (EC 2.3.2.2), a membrane-bound enzyme that degrades GSH and allows the uptake of the products into the cell, is inhibited by acivicin (AT-125) [3] . Most cells cannot take up GSH intact; however, renal proximal tubule cells, small intestinal enterocytes, and alveolar type II cells are able to take up intact GSH [4] .
GSH has an important role in protection of cells from electrophilic toxicants. Electrophilic chemicals (such as diethyl maleate, DEM) can deplete cellular glutathione via glutathione transferase-catalyzed conjugation to GSH and subsequent degradation of the glutathione. The effects of toxicants on reproduction have become of greater importance as couples reproduce at later ages and are increasingly concerned with impaired fertility [5] . The mammalian oocyte and preimplantation embryo are targets for adverse effects of toxicants [6] , and the mechanisms functioning in these tissues to protect them from toxicants are not well understood.
In addition to its roles in protection from toxicants and reactive oxygen species, glutathione functions in processes unique to reproduction and early development. Upon entry into the oocyte, the sperm nucleus decondenses and becomes the pronucleus. The ability of hamster oocytes to induce sperm nuclear decondensation varies by stage of maturation and is correlated with high levels of GSH (mature oocytes, 8 mM; germinal vesicle oocytes, 4 mM; pronuclear oocytes, 6 mM) [7] . Blocking GSH synthesis during oocyte maturation prevents sperm nuclear decondensation after fertilization. Inhibition of GSH synthesis for two days preceding ovulation reduces ovum GSH content below 0.20 pmol and results in abnormal development of zygotes due to lack of transformation of the sperm nucleus [8] . Supplementation of culture medium with cysteine increases the GSH content of pig oocytes matured in vitro and subsequent male pronucleus formation [9] . Chemically induced oxidation of oocyte GSH disrupts normal microtubule function and fertilization of hamster oocytes [10] . These studies demonstrate that GSH has an important role during fertilization of the oocyte.
Our earlier studies demonstrated that GSH concentration decreases 90% from the unfertilized oocyte to the blastocyst stage [11] . GSH concentration decreases from 7 mM to 0.7 mM during this period of development, while the total mass of the embryo remains constant. We have also demonstrated that the mouse embryo has substantial glutathione peroxidase and glutathione reductase activity throughout preimplantation development [11, 12] . However, the preimplantation mouse embryo does not have the capacity for de novo synthesis of GSH until the blastocyst stage, and further development in vitro is adversely affected by low levels of GSH-depleting or -oxidizing chemicals [11] [12] [13] .
The lack of GSH synthesis in the cleavage-stage embryo indicates a deficiency in critical pathways necessary for the protection of cells from toxicants and reactive oxygen species. In vitro, the preimplantation embryo appears to be more sensitive to GSH-depleting agents [13] than the postimplantation embryo [14] . However, in vivo, there may be maternal mechanisms functioning to protect the preimplantation embryo from GSH-depleting agents. At the preimplantation stages of development, the embryo is free-float-
TC # 269
ing in the lumen of the reproductive tract, and it is possible that secretions in the reproductive tract protect the embryo from the adverse effects of GSH depletion. The embryo may recover from GSH-depleting agents by the uptake or use of GSH in the fluid of the maternal reproductive tract. Other extracellular secretions have been shown to contain GSH that functions to protect cells from reactive chemicals and oxidative stress [4] . GSH is present in bile, alveolar lining fluid, cerebrospinal fluid, saliva, sweat, seminal fluid, and milk. Intracellular concentrations of GSH range from approximately 1 to 10 mM, whereas extracellular GSH concentration is usually in the 1-to 10-M range. Some cells contain a sodium-dependent GSH transporter that can take up GSH against this large concentration gradient. It is unknown whether the preimplantation embryo has either this GSH transporter or ␥-glutamyl transpeptidase activity.
Our earlier studies indicate that the cleavage-stage embryo is deficient in the capacity to synthesize GSH and is sensitive to low levels of GSH-oxidizing or -depleting chemicals in vitro. A proposed hypothesis is that, in vivo, the cleavage-stage embryo is protected from toxicants and reactive oxygen species that deplete GSH by the presence of GSH in the fluid of the maternal reproductive tract. We investigated this hypothesis by measuring GSH in secretions from the female reproductive tract and determining whether extracellular GSH is beneficial to embryos with abnormally low intracellular concentrations of GSH.
MATERIALS AND METHODS

Materials
All chemicals were purchased from Sigma (St. Louis, MO) except for the dye for the protein assay, which was purchased from Bio-Rad (Hercules, CA). NSA (colony 202) mice were purchased from Harlan (Indianapolis, IN), and mice for these experiments were bred from these animals.
Superovulation, Embryo Collection, Embryo Evaluation, and Embryo Culture
Pubertal NSA female mice were synchronized and superovulated by i.p. injection of 10 IU eCG followed 44-48 h later with 5 IU hCG. Females were mated with proven breeder males, and copulation was verified by the presence of vaginal plugs the following morning. For embryo collection, mice were killed by cervical dislocation, and their oviducts were removed. The day of detection of the vaginal plug was designated Day 0 of embryo development. Twocell-stage embryos were collected on the afternoon of Day 1. Embryos were collected by flushing the oviducts with M16 medium [15] , selected for normal morphology based on accepted criteria, and washed by sequential passage of embryos through a minimum of five 50-l drops of culture medium. Embryos were cultured in groups of 10-30 embryos in 10-l drops of M16 medium with 4 mg/ml BSA [15] under paraffin oil in a humidified atmosphere of 5% CO 2 in air at 37ЊC. Medium was also supplemented with cystine as a source of cysteine for GSH synthesis to allow for GSH recovery after depletion of cellular stores with DEM [13] . Culture medium was supplemented with cystine to a final concentration of 50 M based on reports of embryonic uptake of cystine at this concentration [13, 16] . Embryos were microscopically evaluated, and indications of fertilization, stage of development, quality of embryos, and abnormal features were recorded. All embryos for replications of an experiment were collected at the same time of day, and for each day the embryos were pooled and randomly distributed to treatment groups. A minimum of nine culture drops of embryos per treatment were used for developmental evaluation.
HPLC Detection of GSH and GSSG
Measurement of GSH and GSSG in pools of embryos (10-40 embryos per measurement) was conducted by fluorescent labeling of glutathione and HPLC analysis. We used the chromatographic techniques developed by Reed and coworkers (aminopropyl silica column with a methanol-sodium acetate gradient system) [17] , but with dansyl chloride as a fluorescent label [18] . Pools of embryos were extracted for glutathione and derivatized with dansyl chloride as reported for other cell types, except in smaller volumes [18] . GSH and GSSG were quantified by comparing integrated peak areas of samples to peak areas in the standard curves (GSH and GSSG), and in comparison to the internal standard (␥-glutamylglutamate). Data are expressed as amount of GSH per whole embryo based on the mean of all replications, and each measurement was replicated a minimum of three times.
The concentration of GSSG in embryonic samples in these experiments was usually below the detection limit and is not reported. We have previously shown that the GSSG content of control blastocysts is 0.002 pmol/embryo [12] . The detection limit of our analysis system is 1 pmol GSSG (signal-to-noise ratio of 3:1). DEM, AT-125, and BSO would not be expected to cause oxidation of GSH to GSSG.
Preparation of Culture Medium with DEM, AT-125, GSH, and BSO
DEM was used to deplete embryonic GSH, BSO was used to inhibit synthesis of GSH, and AT-125 was used to block the breakdown of extracellular GSH on embryonic membranes. GSH, BSO, and AT-125 were diluted in M16 medium to a final concentration of 1 mM GSH, 200 M BSO, and 20 M AT-125. DEM was first dissolved in dimethyl sulfoxide (DMSO) and subsequently diluted with M16 medium before addition of 1 l to each 10-l microdrop, for a final DEM concentration of 60 M and a final DMSO concentration of 1 mM. The DEM was diluted and added to microdrops immediately before culture of embryos. At this concentration of DMSO, no effect was observed on embryo development or GSH and GSSG content due to DMSO alone.
Determination of GSH Content of Mouse Embryos Treated with DEM and GSH
Embryos were collected from mice on Day 1 of development (day of detection of vaginal plug was designated Day 0), selected for normal morphology, washed in medium, and placed into microdrops of culture medium in dishes. DEM was added to some culture plates. After 30 min, embryos were washed to remove DEM by sequential passage through eight 50-l culture drops. Subsequently, embryos were placed into drops in culture plates containing various media and designated C, D, DG, DGB, or DGA as follows. Embryos that had not been treated with DEM were designated C and were placed in control medium (M16 ϩ cystine). Embryos that were treated with DEM were designated D and placed in control medium, DG and placed in GSH medium (control medium ϩ 1 mM GSH), DGB and placed in BSO and GSH medium, or DGA and placed in AT-125 and GSH medium. At the end of 16, 40, or 64 h of incubation, the embryos were washed by sequential passage through a minimum of eight 50-l microdrops, and a sample of medium was analyzed from the last drop to verify the absence of GSH carryover to the embryo sample. After being washed, the embryos were placed into microtubes for glutathione extraction, fluorescent labeling, and HPLC analysis.
Determination of the Developmental Potential In Vitro of Two-Cell-Stage Embryos Treated with DEM, GSH, BSO, and AT-125
Embryos were collected on Day 1 of development at the two-cell stage and treated and labeled as defined above. Developmental progression was microscopically evaluated every 24 h, and stage of development was recorded. The percentages of embryos that developed to the morula, blastocyst, expanded blastocyst, and initiating hatching blastocyst stages were compared.
Collection of Reproductive Tract Flushings
Female mice were bred and checked for the presence of copulation plugs the following morning. The day after plug detection was designated Day 1 of development, and reproductive tract flushings were collected on this day. Mice were killed by cervical dislocation, and their reproductive tract was gently lifted away from the other organs. The reproductive tract was supported by inserting forceps under the tract and was rinsed with buffer containing 50 mM Hepes and 2 mM diethylenetriaminepentaacetic acid (pH 7.4; to prevent oxidation of GSH to GSSG). The uterus was clamped off at the cervix and flushed with 80-l buffer. Flushing buffer was inserted via a 30-gauge needle attached to a 1-cc syringe. Using the same syringe, the flushing buffer containing reproductive tract secretions was subsequently aspirated and transferred to a microcentrifuge tube. The reproductive tract was then removed, rinsed with buffer, and transferred to a watch glass. The reproductive tract was positioned in the dish so that the cut ends of the tract were not touching the inside of the dish. The oviducts were flushed with buffer using a 30-gauge needle and a 1-cc syringe inserted at the uterotubal junction, the fluid was aspirated from the watch glass, and the oviduct flushing was transferred to a microcentrifuge tube. After all samples were collected, they were centrifuged at 13 000 ϫ g for 10 min to remove cells. The supernatant was transferred to clean microcentrifuge tubes, and 50 l of the sample was used for quantification of GSH using the protocol described above. Ten microliters of the sample was analyzed for protein concentration using a modification of the Bradford method [19] .
Statistical Analysis
Differences in morphological development and fertilization rate were determined using chi-square analysis. Differences in GSH and GSSG content were determined using ANOVA and Fisher's least-significant-difference method. Values represent means of all replicates, and each value represents a minimum of three replications. Embryos were recovered from ten or more females and randomly distributed to treatments. The number of embryos used for each glutathione measurement varied from 10 to 40 embryos because of the availability of embryos on each particular day and the necessity to use larger numbers of embryos under some conditions to obtain a good signal-to-noise ratio on the chromatogram. The developmental data were collected from a minimum of nine culture drops of embryos (10 
RESULTS
Developmental Potential In Vitro of Two-Cell-stage Embryos Treated with DEM, GSH, BSO, and AT-125
We were interested in whether GSH-depleted embryos cultured in the presence of GSH exhibit improved development and, if so, in the mechanism by which extracellular GSH aids the embryo. Two-cell-stage embryos were collected on the afternoon of Day 1 and cultured and treated as described in Materials and Methods. Percentages of twocell-stage embryos developing to the morula, blastocyst, expanded blastocyst, and initiating hatching blastocyst stages in the various treatments were evaluated (Fig. 1) . More (p Ͻ 0.05) GSH-depleted embryos cultured in GSHsupplemented medium developed to the morula stage than did those DEM-treated embryos cultured in control medium (% morula: DG ϭ 96, D ϭ 87). Although more DG embryos developed to the blastocyst, expanded blastocyst, and initiating hatching blastocyst stages (% blastocyst: DG ϭ 78, D ϭ 75; % expanded blastocyst: DG ϭ 58, D ϭ 54; % initiating hatching blastocyst: DG ϭ 21, D ϭ 17), this increase was not significant. If the beneficial effects of GSH are due to breakdown of the GSH at the cell membrane and uptake of the components, then the addition of AT-125 should block the beneficial effects of GSH. Results indicated that AT-125 completely blocked development to the blastocyst stage and caused most of the embryos to degenerate by 16 h of culture (% morula: DGA ϭ 29; % blastocyst: DGA ϭ 0; % expanded blastocyst: DGA ϭ 0; % initiating hatching blastocysts: DGA ϭ 0; p Ͻ 0.01). BSO blocked de novo synthesis of GSH and had a negative effect on development to the blastocyst, expanded blastocyst, and initiating hatching blastocyst stages (% blastocyst: DGB ϭ 43; % expanded blastocyst: DGB ϭ 33; % initiating hatching blastocysts: DGB ϭ 5). No effect was seen on the percentage of embryos developing to the morula stage due to BSO (% morula DGB ϭ 97). This is to be expected because morula-stage embryos do not have the capacity for de novo synthesis of GSH. GSH-depleted embryos that were cultured in the presence of GSH exhibited improved development to later stages compared to GSHdepleted embryos that were not cultured in the presence of GSH, and the addition of BSO or AT-125 blocked the beneficial effects of GSH in the culture medium (p Ͻ 0.05; Fig. 1 ).
GSH Content of Mouse Embryos Treated with DEM and GSH
The purpose of these measurements was to determine whether extracellular GSH could be used by the GSH-depleted embryo to recover its intracellular GSH. Two-cellstage embryos were treated with DEM for 30 min and then cultured for 16, 40, or 64 h in control or GSH-supplemented medium before quantitation of GSH content. At 16 h of incubation, most of the embryos were morulas, and the DEM-treated embryos had significantly lower GSH concentrations than did the control embryos ( Fig. 2 ; p Ͻ 0.05; C ϭ 0.42 pmol GSH/embryo, D ϭ 0.16 pmol GSH/ embryo, DG ϭ 0.10 pmol/embryo). No significant differences were observed in the GSH content of D and DG embryos at any time point. By 40 h of incubation, most of the embryos were blastocysts. At this time, the GSH content of control embryos had decreased to 0.24 pmol GSH/ embryo, and the DEM-treated embryos still had significantly less GSH (p Ͻ 0.05; D ϭ 0.15 pmol/embryo, DG ϭ 0.14 pmol/embryo). By 64 h of incubation, there was no significant difference in the GSH content of the embryos (C ϭ 0.21 pmol/embryo, D ϭ 0.20 pmol/embryo, DG ϭ 0.17 pmol/embryo). Most of the DGA embryos had degenerated by 16 h of incubation, so GSH content was not determined in DGA embryos. The GSH content of DGB embryos was only determined at 64 h of incubation, when it was significantly lower than in DG embryos (not shown on figure; 0.06 Ϯ 0.03 pmol GSH/embryo). The GSH concentration of the control embryos decreased during the 64 h of incubation as in previous studies. We did not find a significant increase in GSH content of DEM-treated embryos due to the presence of GSH in the culture medium (Fig. 2) .
Glutathione Content of Reproductive Tract Flushings
The purpose of these measurements was to determine the concentration of GSH and GSSG in the secretions of the female reproductive tract. Reproductive tract flushings were collected from the oviducts and uteri of female mice on Day 1 of pregnancy. At this time the embryo is at the two-cell stage and unable to synthesize GSH de novo. The concentration of glutathione in the reproductive tract flushing was expressed as nmol glutathione per mg protein (Fig.  3) . No significant difference was found in the concentrations of GSH, GSSG, or total glutathione in the oviduct or uterus. The GSH content of control embryos after 16 h of incubation was 0.42/embryo. Expressed in the same units as the reproductive tract flushings, these cleavage/morulastage embryos had approximately 17.5 nmol GSH/mg protein. Total glutathione was determined by multiplying the concentration of GSSG by two and adding that number to the concentration of GSH. The percentage of the total glutathione that was oxidized was calculated by multiplying the concentration of GSSG by two and dividing that number by the total glutathione concentration. The percentage of the total glutathione that was oxidized was 25% in the oviduct and 33% in the uterus.
DISCUSSION
This study investigated the hypothesis that GSH in the reproductive tract fluid protects the preimplantation embryo from the adverse effects of intracellular GSH depletion. GSH has important functions in protecting cells from reactive oxygen species and toxicants [1] . Unlike other cell types that have been studied, the cleavage-stage mouse embryo does not have the capacity to synthesize GSH de novo [13] . For this reason, the preimplantation embryo may be adversely affected by reactive oxygen species and toxicants even at low levels. Alternatively, in vivo the preimplantation embryo may be able to utilize GSH from the secretions of the reproductive tract to recover from the adverse effects of intracellular GSH depletion. Our study supports this possibility by demonstrating that GSH is present in reproductive tract fluid and that addition of GSH to culture medium improves the development of GSH-depleted embryos. Surprisingly, the improved development was not correlated with an increase in the intracellular GSH content of the embryos, and it is not clear how the extracellular GSH benefits the embryo.
The GSH concentration of the preimplantation embryo decreases continuously from the unfertilized oocyte to the blastocyst stage so that the GSH concentration in the blastocyst is approximately 0.7 mM compared to 7 mM in the unfertilized oocyte [11] . This decrease in the GSH concentration of the embryo appears to be a normal part of early development and may have an important role in the regulation of apoptosis of redundant cells in the embryo [20] . Studies suggest that hydrogen peroxide in blastocoel fluid induces apoptosis of redundant cells within the blastocyst and that those cells that survive and continue development are protected via a glutathione-dependent mechanism. The preimplantation embryo is unable to synthesize GSH de novo until the blastocyst stage and is unable to recover from GSH depletion in vitro until this time. Treatment of embryos in vitro with low levels of chemicals that deplete GSH, such as DEM, results in decreased development to later stages. The preimplantation embryo appears to be more sensitive to GSH depletion than other tissues such as the postimplantation embryo [14] . Embryos that develop in vitro have decreased GSH concentrations compared to embryos that develop in vivo [11] . This may be due to increased oxidative stress in vitro or to the embryo's use of GSH in the maternal reproductive tract in vivo. Most mammalian cell types studied do not take up GSH intact but instead break the GSH down at the membrane and take up the components that can be utilized for intracellular GSH synthesis [4] . Some types of cells are capable of taking up GSH intact [4] , but it was unknown whether the preimplantation embryo can do this.
GSH was detected in the flushings from the mouse oviduct and uterus. We found that the flushings of the oviduct had approximately 51 nmol GSH/mg protein compared to 17.5 nmol GSH/mg protein in the preimplantation embryo. The volume of fluid in the reproductive tract before flushing could not be accurately determined, so we cannot express the GSH value as the mM concentration in the reproductive tract secretions. Typically, extracellular GSH concentration is much less than intracellular GSH concentration. However, GSH is present in other extracellular fluids and has been shown to protect cells from oxidative damage [4] . Extracellular GSH also appears to have a protective function for the preimplantation embryo, although it is unclear whether the concentration of GSH in the secretions of the reproductive tract changes during the estrous cycle or gestation, how sensitive it is to alteration by oxidative stress and toxicants, and how important it is to normal development in vivo. Furthermore, the secretions of the reproductive tract may contain many other molecules that are important to normal development, and GSH in the reproductive tract may have functions in addition to a direct effect on the embryo.
We found that the DEM-treated embryo did benefit from the presence of GSH in culture medium but did not exhibit a significant increase in intracellular GSH. We depleted 80% of embryonic GSH with DEM (to the level normally found in the blastocyst) and found a small effect on development. Our previous studies have shown that depletion below this level results in loss of embryo viability. Addition of GSH to the culture medium improved development to the morula stage without recovering intracellular GSH. It is unclear how the GSH exerts its beneficial effect. AT-125 blocked the effect of GSH, suggesting that it may be necessary for GSH to be broken down by ␥-glutamyl transpeptidase to be beneficial to the embryo. However, the AT-125 completely blocked development past the morula stage and was toxic to the embryo. Studies with cultured rat embryos also demonstrate that AT-125 is toxic to postimplantation embryos and may have effects other than inhibition of ␥-glutamyl transpeptidase [21] . We had supplemented the culture medium with cystine at a concentration that we have previously shown to be adequate to support GSH synthesis in the blastocyst, so it is unlikely that the GSH exerts its beneficial effect by serving as a source of cysteine. It is possible that the transport mechanisms for cystine are not adequate at the cleavage/morula stages and, therefore, breakdown of GSH as a source of cysteine is beneficial. However, studies with ␥-glutamyl transpeptidase knockout mice have demonstrated that ␥-glutamyl transpeptidase activity is not essential for prenatal development in the mouse [22] .
Addition of BSO to the culture medium did not affect development to the morula stage but did affect development to later stages. Because the embryo cannot synthesize GSH until the blastocyst stage, we would expect blocking GSH synthesis to first affect the embryo at this stage. In our previous studies, the addition of BSO to culture medium blocked synthesis of GSH in the blastocyst, decreased the GSH content of the embryo, and decreased the percentage of embryos developing to later stages [12, 13] . We were interested in determining whether a BSO-induced lack of GSH synthesis could trigger GSH uptake in the blastocyst. The addition of GSH to the culture medium was unable to protect against the adverse effects of BSO or to return intracellular GSH to normal levels. The lack of effect of BSO on development to the morula stage further indicates that the improvement in development to the morula stage due to GSH in the culture medium was not caused by the utilization of the amino acids from the GSH in the culture medium for the resynthesis of GSH inside the embryo. Also, we found no significant difference in the GSH content of D and DG embryos, again demonstrating that the beneficial effect of extracellular GSH was not due to increasing embryonic GSH content.
Extracellular GSH may also benefit the DEM-treated embryo by conditioning the medium or by having effects on extracellular domains of membrane proteins or other molecules. GSH can function as a redox buffer and help maintain important sulfhydryl bonds in the reduced state. Furthermore, GSH may nonenzymatically scavenge reactive oxygen species in the medium or on the extracellular surfaces of the embryo, preventing them from causing damage to membrane molecules. Na/K ATPase is a sulfhydrylcontaining membrane protein that is important in formation of the blastocoel [23] . Reactive oxygen species in the culture medium may cause lipid peroxidation in the embryo, which has been shown to decrease Na/K ATPase activity [24] . Finally, other studies have demonstrated that extracellular GSH protects cell surface proteins from oxidative damage [4] .
Our study demonstrates that GSH is present in reproductive tract secretions and that extracellular GSH is beneficial to GSH-depleted preimplantation embryos. This study also suggests that the preimplantation embryo is not capable of taking up intact GSH. Because the cleavagestage embryo is also unable to synthesize GSH, it appears to have no mechanism for recovery of GSH after depletion. Therefore, the preimplantation embryo may be particularly vulnerable to GSH-depleting chemicals and conditions. In TC # 269 addition, if the oocyte develops under conditions that result in decreased oocyte GSH, the resulting embryo will not be able to recover its intracellular GSH until the blastocyst stage. Decreased embryonic GSH concentration may leave the embryo susceptible to further insult from toxicants and endogenous reactive oxygen species, potentially leading to damage to DNA and other cellular macromolecules.
